


## Development of New Synthetic Method of the DFGH-ring of Physalin-Type Natural Products and SAR Study of the Pseudo-Natural Products

(<sup>1</sup>Graduate School of Pharmaceutical Science, Kyushu University, <sup>2</sup>RIKEN) ○ Makoto Yoritate,<sup>1</sup> Yuki Morita,<sup>1</sup> Manuel Gemander,<sup>2</sup> Masaki Morita,<sup>1,2</sup> Tomohiro Yamashita,<sup>1</sup> Mikiko Sodeoka,<sup>2</sup> and Go Hirai<sup>1,2</sup>

**Keywords:** Physalin; Steroid; Domino Reaction; Cascade Reaction; Structure-Activity Relationship

Physalins are steroidal constituents of *Physalis* plants and contain a complex, highly oxygenated fused-ring system. More than 30 physalin-type natural products have been isolated so far, and most of them possesses a highly fused and oxygenated DEFGH-ring structure like that of physalin B (**1**). The significance of the left-side (AB-ring) structure of **1** for biological activity is well established, but the importance of the right-side (D(E)FGH-ring) structure has long been unclear. Based on our previous study,<sup>1)</sup> we designed the simplified DFGH-ring structure **2** with the hydrophobic substituent (**R**) at C17, which may exhibit high inhibitory activity of NF-κB activation.

Since the right-side structure of physalin B (PBright) possesses a highly functionalized and fused ring structure, we required a robust synthetic route to **5** involving mild reaction conditions. In particular, the key GH-ring construction previously achieved via the base-mediated domino ring-opening/closure sequence (**3**→**4**→**5**→**6**)<sup>2)</sup>, was problematic due to a bias of the equilibrium towards the more stable **5** rather than the desired **6**. During the synthetic study, we found an alternative synthetic route toward **2** via newly found domino sequence of **7** to directly give DFGH-ring compound **8**. Here we present the synthesis and SAR study of **2**.<sup>3)</sup>



1) Ozawa, M.; Morita, M.; Hirai, G.; Tamura, S.; Kawai, M.; Tsuchiya, A.; Oonuma, K.; Maruoka, K.; Sodeoka, M., *ACS Med. Chem. Lett.* **2013**, 4, 730–735. 2) Ohkubo, M.; Hirai, G.; Sodeoka, M., *Angew. Chem. Int. Ed.* **2009**, 48, 3862–3866. 3) Yoritate, M.; Morita, Y.; Gemander, M.; Morita, M.; Yamashita, T.; Sodeoka, M.; Hirai, G., *Org. Lett.* **2020**, 22, 8877–8881.